(Q37857918)

24 August 2017

1 reference

title

Multisite international collaborative clinical trials in mania (English)

1 reference

24 August 2017

1 reference

Gustavo Vázquez

1

1 reference

24 August 2017

Ross J Baldessarini

2

1 reference

24 August 2017

Ayşegül Yildiz

3

1 reference

24 August 2017

Jorge Tamayo

4

1 reference

24 August 2017

Leonardo Tondo

5

1 reference

24 August 2017

Paola Salvatore

6

1 reference

24 August 2017

publication date

25 March 2011

1 reference

The International Journal of Neuropsychopharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

14

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1013-1016

1 reference

Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Ethical considerations in industry‐sponsored Multiregional clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Conflicts of interest in research involving human beings.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Ethical and scientific implications of the globalization of clinical research

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Multi-national clinical therapy studies. Design, management and costs

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Multicentre trials: a US regulatory perspective

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Sample size allocation to regions in a multiregional trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Valproate in the treatment of acute mania. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Cultural adaptations of current psychiatric classifications: are they the solution?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000447

7 January 2021

10.1017/S1461145711000447

Identifiers

DOI

1 reference

24 August 2017

1 reference